Dissecting the antibody-OME: past, present, and future

Carolin Loos; Douglas A Lauffenburger; Galit Alter

doi:10.1016/j.coi.2020.06.003

Dissecting the antibody-OME: past, present, and future

Curr Opin Immunol. 2020 Aug:65:89-96. doi: 10.1016/j.coi.2020.06.003. Epub 2020 Aug 2.

Authors

Carolin Loos¹, Douglas A Lauffenburger², Galit Alter³

Affiliations

¹ Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
² Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
³ Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: galter@mgh.harvard.edu.

PMID: 32755751
DOI: 10.1016/j.coi.2020.06.003

Abstract

Humoral immunity is key to protection for nearly all licensed vaccines. Yet, the design of vaccines has been more difficult for some of our most deadly killers (e.g. HIV, influenza, Dengue virus, etc.), likely due to our incomplete understanding of the precise immunological mechanisms associated with protection. Humoral immunity is governed both by B-cells and their bi-functional secreted antibodies, all of which have a unique capacity to evolve during an immune response. Current OMIC technologies capture individual features of the humoral immune response, providing a glimpse into humoral components (Fab/Fc/B-cell-omic), but fail to provide a wholistic view of the humoral response as a collective functional arm. Here, we dissect current OMIC strategies reviewing experimental and computational approaches, that if integrated could provide a true systems-level view of the humoral immune response.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Antibodies, Viral / immunology*
Humans
Immunity, Humoral / immunology*

Substances

Antibodies, Viral

Abstract

Publication types

MeSH terms

Substances

Grants and funding